<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113069</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A1912-I-101</org_study_id>
    <nct_id>NCT05113069</nct_id>
  </id_info>
  <brief_title>A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas</brief_title>
  <official_title>An Open-Label, Single-Arm, Multicenter, Phase I Study to Estimate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1912 in Patients With B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hengrui Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Hengrui Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to&#xD;
      determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended&#xD;
      phase II dose (RP2D) of SHR-A1912.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single arm for SHR-A1912</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>21 Days after the 1st dosing (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limited Toxicity (DLT)</measure>
    <time_frame>21 Days (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerable dose (MTD)</measure>
    <time_frame>21 Days (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose (RP2D)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of SHR-1912</measure>
    <time_frame>21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of SHR-1912</measure>
    <time_frame>21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of SHR-1912</measure>
    <time_frame>21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) of SHR-A1912</measure>
    <time_frame>12 weeks after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-A1912</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1912</intervention_name>
    <description>SHR-A1912, dose escalation and expansion.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age greater than or equal to18 years old, male or female;&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1;&#xD;
&#xD;
          3. Life expectancy &gt;12 weeks;&#xD;
&#xD;
          4. Histologically or cytologically confirmed B cell lymphoma;&#xD;
&#xD;
          5. Relapsed and/or refractory disease after at least 1 prior treatment regimen;&#xD;
&#xD;
          6. At least one measurable nodal lesion, defined as &gt; 1.5 cm in its longest dimension, or&#xD;
             one measurable extra nodal lesion, defined as &gt; 1.0 cm in its longest diameter (no&#xD;
             need for dose escalation stage).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received autologous stem cell transplantation within 12 weeks before the first study&#xD;
             treatment; previously received allogeneic stem cell transplantation or Car-T cell&#xD;
             therapy;&#xD;
&#xD;
          2. History of recent major surgery or severe trauma within 4 weeks before the first study&#xD;
             treatment;&#xD;
&#xD;
          3. Received anti-tumour treatment within 2 weeks before the first study treatment;&#xD;
&#xD;
          4. Central nervous system (CNS) infiltration;&#xD;
&#xD;
          5. Active infection with HBV or HCV;&#xD;
&#xD;
          6. History of immunodeficiency, including HIV serotest positive, or other acquired or&#xD;
             congenital immunodeficiency diseases, and active tuberculosis;&#xD;
&#xD;
          7. Active infection or unexplained fever&gt;38.5â„ƒ;&#xD;
&#xD;
          8. History of severe cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiwei Wang</last_name>
    <phone>86-021-23511999</phone>
    <email>wewei.wang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shouwei Zhao</last_name>
    <phone>86-010-67166319</phone>
    <email>shouwei.zhao@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

